Validation of in vivo endpoint effects of the drugs on early atherosclerosis. Atherosclerotic lesion area determined in the aortic valve area of ApoE3Leiden mice treated with an atherogenic high cholesterol diet (HC) in the presence or absence of rosuvastatin (RSV), fenofibrate (FF) and LXR agonist T0901317 (T09). *P<0.05 versus HC (ANOVA and least significant difference post-hoc testing).
Kleemann et al. BMC Systems Biology 2011 5:125 doi:10.1186/1752-0509-5-125